Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence

Endocrine-Related Cancer

Volumn 21, Issue 2, 2014, Pages 343-353

  Choi, Won Mook ^a   Lee, Jeong Hoon ^a   Yoon, Jung Hwan ^a   Kwak, Cheol ^b   Lee, Young Ju ^b   Cho, Young Youn ^a   Lee, Yun Bin ^a   Yu, Su Jong ^a   Kim, Yoon Jun ^a   Kim, Hyeon Hoe ^b   Kim, Hyo Cheol ^c   Cho, Sung Yong ^d   Lee, Seung Bae ^d   Jeong, Hyeon ^d   Kim, Chung Yong ^a   Lee, Hyo Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Department of Urology ^*  (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University Boramae Hospital   (South Korea)

Author keywords

Biochemical recurrence; Nonalcoholic fatty liver disease; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FIBROSIS; FOLLOW UP; GLEASON SCORE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PROSTATE CANCER; PROSTATECTOMY;

BIOCHEMICAL RECURRENCE; NONALCOHOLIC FATTY LIVER DISEASE; PROSTATE CANCER; RADICAL PROSTATECTOMY;

AGED; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; REPUBLIC OF KOREA; RISK FACTORS;

EID: 84899833653     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0036     Document Type: Article

References (46)

1. Albanes D, Weinstein SJ, Wright ME, Männistö S, Limburg PJ, Snyder K & Virtamo J 2009 Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. Journal of the National Cancer Institute 101 1272-1279. (doi:10.1093/jnci/djp260)
2. Angulo P 2002 Nonalcoholic fatty liver disease. New England Journal of Medicine 346 1221-1231. (doi:10.1056/NEJMra011775)
3. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD & Bida JP 2007 The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 846-854. (doi:10.1002/hep.21496)
4. Arturi F, Succurro E, Procopio C, Pedace E, Mannino GC, Lugarà M, Procopio T, Andreozzi F, Sciacqua A & Hribal ML 2011 Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. Journal of Clinical Endocrinology and Metabolism 96 E1640-E1644. (doi:10.1210/jc.2011-1227)
5. Bohte AE, van Werven JR, Bipat S & Stoker J 2011 The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. European Radiology 21 87-97. (doi:10.1007/s00330-010-1905-5)
6. Bravo AA, Sheth SG & Chopra S 2001 Liver biopsy. New England Journal of Medicine 344 495-500. (doi:10.1056/NEJM200102153440706)
7. Cao Y & Ma J 2011 Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prevention Research 4 486-501. (doi:10.1158/1940-6207.CAPR-10-0229)
8. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M & Sanyal AJ 2012 The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 2005-2023. (doi:10.1002/hep. 25762)
9. Chun FK-H, Graefen M, Zacharias M, Haese A, Steuber T, Schlomm T, Walz J, Karakiewicz PI & Huland H 2006 Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World Journal of Urology 24 273-280. (doi:10.1007/s00345-006-0058-2)
10. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I & Beard CJ 1998 Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Journal of the American Medical Association 280 969-974. (doi:10.1001/jama.280.11.969)
11. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E & Parsons JK 2012 The correlation between metabolic syndrome and prostatic diseases. European Urology 61 560-570. (doi:10.1016/j.eururo.2011.11.013)
12. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltrán L, Moats S, Ramirez A, Jorcano J & Conti C 2000 Deregulated expression of insulinlike growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. PNAS 97 3455-3460. (doi:10.1073/pnas.97.7.3455)
13. Edge SB & Compton CC 2010 The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of Surgical Oncology 17 1471-1474. (doi:10.1245/s10434-010-0985-4)
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Journal of the American Medical Association 285 2486-2497. (doi:10.1001/jama. 285.19.2486)
15. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF & Wang AT 2010 Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism 95 2560-2575. (doi:10.1210/jc.2009-2575)
16. Fusco A, Miele L, D'Uonnolo A, Forgione A, Riccardi L, Cefalo C, Barini A, Bianchi A, Giampietro A & Cimino V 2012 Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clinical Endocrinology 77 531-536. (doi:10.1111/j.1365-2265.2011. 04291.x)
17. Haheim LL, Wisløff T, Holme I & Nafstad P 2006 Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. American Journal of Epidemiology 164 769-774. (doi:10.1093/aje/kwj284)
18. Han M, Partin AW, Pound CR, Epstein JI & Walsh PC 2001 Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urologic Clinics of North America 28 555-565. (doi:10.1016/S0094-0143(05)70163-4)
19. Hsing AW, Sakoda LC & Chua SC 2007 Obesity, metabolic syndrome, and prostate cancer. American Journal of Clinical Nutrition 86 843S-857S.
20. Jones JI & Clemmons DR 1995 Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 16 3-34.
21. Kasper JS & Giovannucci E 2006 A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 15 2056-2062. (doi:10.1158/1055-9965.EPI-06-0410)
22. Kasper JS, Liu Y & Giovannucci E 2009 Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. International Journal of Cancer 124 1398-1403. (doi:10.1002/ijc.24044)
23. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim S-K, Kim KR, Lee HC & Huh KB 2004 Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Archives of Internal Medicine 164 2169. (doi:10.1001/archinte.164.19.2169)
24. Kim S, Kwon H, Park J-H, Cho B, Kim D, Oh S-W, Lee CM & Choi H-C 2012 A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterology 12 69. (doi:10.1186/1471-230X-12-69)
25. Lawrence Y, Morag O, Benderly M, Boyko V, Novikov I, Dicker A, Goldbourt U, Behar S, Barchana M & Wolf I 2013 Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer and Prostatic Diseases 16 181-186. (doi:10.1038/pcan.2012.54)
26. Lee SE, Lee WK, Jeong MS, Abdullajanov M, Kim DS, Park HZ, Jeong SJ, Yoon CY, Byun SS & Choe G 2011 Is body mass index associated with pathological outcomes after radical prostatectomy in Korean men? BJU International 107 1250-1256. (doi:10.1111/j.1464-410X.2010. 09592.x)
27. Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M & Gonzalgo ML 2008 Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology 72 1246. (doi:10.1016/j.urology. 2008.01.052)
28. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G & Melchionda N 1999 Association of nonalcoholic fatty liver disease with insulin resistance. American Journal of Medicine 107 450-455. (doi:10.1016/S0002-9343(99)00271-5)
29. Martin RM, Vatten L, Gunnell D, Romundstad P & Nilsen TI 2009 Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes & Control 20 1181-1192. (doi:10.1007/s10552- 009-9319-x)
30. Morgentaler A & Traish AM 2009 Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. European Urology 55 310-321. (doi:10.1016/j. eururo.2008.09.024)
31. Musso G, Gambino R, Cassader M & Pagano G 2011 Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine 43 617-649. (doi:10.3109/07853890.2010.518623)
32. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Keum DK & Kim BI 2006 Prevalence and risk factors of non alcoholic fatty liver disease among Korean adults. Journal of Gastroenterology and Hepatology 21 138-143. (doi:10.1111/j.1440-1746.2005.04086.x)
33. Pickhardt PJ, Park SH, Hahn L, Lee S-G, Bae KT & Yu ES 2012 Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. European Radiology 22 1075-1082. (doi:10.1007/s00330-011-2349-2)
34. Porter CR, Kodama K, Gibbons RP, Correa R Jr, Chun FK, Perrotte P & Karakiewicz PI 2006 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. Journal of Urology 176 569-574. (doi:10.1016/j.juro.2006.03.094)
35. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD & Walsh PC 1999 Natural history of progression after PSA elevation following radical prostatectomy. Journal of the American Medical Association 281 1591-1597. (doi:10.1001/jama.281.17.1591)
36. Roddam A, Allen N, Appleby P & Key T 2008 Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute 100 170-183. (doi:10.1093/jnci/djm323)
37. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ & Calle EE 2005 Diabetes and risk of prostate cancer in a prospective cohort of US men. American Journal of Epidemiology 161 147-152. (doi:10.1093/aje/kwh334)
38. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM & Martin RM 2009 Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. International Journal of Cancer 124 2416-2429. (doi:10.1002/ijc.24202)
39. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN & Sheridan MJ 2002 The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 745-750. (doi:10.1053/gast.2002.35354)
40. Svensson J, Kindblom J, Shao R, Movérare-Skrtic S, Lagerquist MK, Andersson N, Sjögren K, Venken K, Vanderschueren D & Jansson J-O 2008 Liver-derived IGF1 enhances the androgenic response in prostate. Journal of Endocrinology 199 489-497. (doi:10.1677/JOE-08-0406)
41. Tande AJ, Platz EA & Folsom AR 2006 The metabolic syndrome is associated with reduced risk of prostate cancer. American Journal of Epidemiology 164 1094-1102. (doi:10.1093/aje/kwj320)
42. Tomaszewski JJ, Chen Y-F, Bertolet M, Ristau BT, Woldemichael E & Nelson JB 2013 Obesity is not associated with aggressive pathologic features or biochemical recurrence after radical prostatectomy. Urology 81 992-996. (doi:10.1016/j.urology.2012.10.080)
43. Torres DM & Harrison SA 2008 Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134 1682-1698. (doi:10.1053/j.gastro. 2008.02.077)
44. Van Gaal LF, Mertens IL & Christophe E 2006 Mechanisms linking obesity with cardiovascular disease. Nature 444 875-880. (doi:10.1038/ nature05487)
45. Van Roermund JG, Kok DE, Wildhagen MF, Kiemeney LA, Struik F, Sloot S, Van Oort IM, Hulsbergen-van de Kaa CA, Van Leenders GJ & Bangma CH 2009 Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy. BJU International 104 321-325. (doi:10.1111/j.1464-410X.2009. 08404.x)
46. Völzke H, Aumann N, Krebs A, Nauck M, Steveling A, Lerch MM, Rosskopf D & Wallaschofski H 2010 Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. International Journal of Andrology 33 45-53. (doi:10.1111/j.1365-2605. 2009.00953.x)